Case Report

Acute Carbamazepine Intoxication

María Dolores Calabria Gallego¹,²,* and Mónica Alañá García²

¹IBSAL, Institute for Biomedical Research of Salamanca, 37007 Salamanca, Spain
²Neurology Department, University Hospital of Salamanca, 37007 Salamanca, Spain; malana@saludcastillayleon.es

*Correspondence: mdcalabria@saludcastillayleon.es

Abstract: Carbamazepine is an anticonvulsant drug with multiple mechanisms of action, which condition the presence of a characteristic clinical picture after the overingestion of the drug. We expose a case report about a patient who, in the context of an attempted suicide, presented acute intoxication by benzodiazepines and carbamazepine, presenting the characteristic clinical picture of fluctuations in the level of consciousness, even presenting gaze deconjugation, almost unreactive coma and generalized hypotonia.

Keywords: carbamazepine; acute intoxication; neurological side effects

1. Introduction

Carbamazepine is an anticonvulsant drug with a wide spectrum of possible therapeutic effects (management of: bipolar disorder [1], impulse control disorder [2], trigeminal neuralgia [3], among others), prescribed by general physicians, psychiatrists, neurologists, . . . Its mechanism of action is related to the blockade of presynaptic voltage—dependent sodium channels [4], leading consequently to inhibition of the release of synaptic glutamate and possibly other neurotransmitters [5]. Furthermore, carbamazepine is also a potent inhibitor of acetylcholine receptors, adenosine receptors, and N-methyl-D aspartate (NMDA) receptors [6]. These mechanisms of action will be involved in the possible side effects derived from carbamazepine intoxication.

Carbamazepine is metabolized in the liver where the epoxide pathway is the most important, giving the 10,11-transdiol derivative and its glucuronide as the main metabolites [7].

Table 1. Correlation between plasma concentrations of carbamazepine and clinical consequences.

| Plasma Concentration | Clinical Expression                                      |
|----------------------|---------------------------------------------------------|
| 4–12 mcg/mL          | Therapeutic range                                       |
| 12–16 mcg/mL         | Ataxia, nystagmus                                        |
| 16–24 mcg/mL         | Obtundation, stupor                                      |
| 24–40 mcg/mL         | Alternating between reactive coma, agitation, hallucinations, choreographic movements |
| 40–60 mcg/mL         | Reactive coma, mydriasis, risk of seizures, decerebrate movements |
| >60 mcg/mL           | Unreactive coma, hypoventilation, cardio toxicity, possible status epilepticus. |

However, the effect of exposure to other central-nervous-system (CNS) acting medications on the neurological manifestations of carbamazepine toxicity has not widely been
evaluated; this practice is especially frequent when attempts of suicide are committed [9].

In the past, we can find reports of patients who ingested large quantities of carbamazepine with alcohol and/or other anticonvulsants. They usually presented obtundation with ataxia, nystagmus, mydriasis, nausea and vomiting. They often manifested hypertonicity, hyper-reflexia and clonus early with hypotonia [10].

It can be difficult to identify this diagnosis; due to other many entities can cause the same neurological effects (Table 2), being one of these, just the one for which this drug is prescribed: seizures.

Table 2. Main causes of sudden onset coma [11].

| Cause                   | Type                                                                 |
|-------------------------|----------------------------------------------------------------------|
| Stroke                  | Ischemic, hemorrhagic                                                |
| Seizure                 | Including non-convulsive status epilepticus                         |
| Drug overdose/toxins    | Opioids, CO, antipsychotics, antidepressants, antiepileptic drugs . . .|
|                         | Hypoglycaemia, hyponatraemia, hypercalcaemia, hyperammonaemia, hepatic encephalopathy . . . |
| Metabolic               |                                                                      |
| Infection               | Including central nervous system infections                          |

2. Case Report

This patient, with personal history of eosinophilic colitis, asthma, and under follow-up in a neurology clinic for long-standing partial epilepsy, treated with carbamazepine, and seizure-free for 5 years, with previous seizures consisting of episodes of staring and disconnection from the environment, sometimes with clonic movements of the extremities. In addition, the patient presented a possible generalized anxiety disorder, for which she had not yet been evaluated by a Mental Health team, although she was being treated for this reason with Alprazolam by her general practitioner. There were no other medical records of interest.

The patient was taken to the Emergency Department by her relatives when she was found fallen, between the bedside table and the bed, with a low level of consciousness, although presenting fluctuations that allowed a coherent language on the way from her home to the hospital. In that moment she confessed having ingested 6 alprazolam tablets. The patient’s relatives found, in fact, an empty blister pack of that drug in the garbage container.

Once in the Emergency Department, two ampoules of intravenous flumazenil were administered to reverse the possible effect of a benzodiazepine intoxication, but as the condition did not improve, it was decided to contact Neurology on call.

The patient was afebrile, with blood pressure of 151/84 mmHg, partial oxygen saturation of 100%, and capillary blood glucose of 198 mg/dL. As for the general examination, she was eupneic, with normal coloration of the skin and mucous membranes, and without signs suggestive of heart failure. On cardiac auscultation, the patient was rhythmic and without murmurs. Pulmonary auscultation in anterior planes showed preserved vesicular murmur, although at times it suggested the presence of hypoventilation. On abdominal palpation, a bladder balloon was detected. There were no edemas, nor signs of deep vein thrombosis.

3. Results

On neurological examination, the patient was found alternating between almost unreactive coma with deconjugated pupils and generalized hypotonia, and an alert level of consciousness with significant psychomotor agitation that required mechanical restraint.

Multimodal cranial computerized tomography (CT) with perfusion sequence was performed (Figures 1 and 2), without alterations; as well as an extensive analysis that showed no alterations of interest, except for the aforementioned hyperglycemia. Levels of toxic substances were requested, detecting high levels of benzodiazepines (>900 mg/dL) and carbamazepine (46.3 mg/dL) (chemiluminescent immunoassay technique with double
checked, was performed). Gastric lavage or activated charcoal administration were not performed due to the long period of time between the possible intake of the drug and the knowledge of the carbamazepine values (more than 8 h).

Figure 1. No intra- or extra-axial bleeding signs of acute ischemia (ASPECTS 10) or occupying lesions were observed in the simple cranial CT.

Figure 2. No alterations are observed in the parametric maps (mean transit time, flow or brain volume) suggesting acute cerebral ischemia.

The patient was transferred to the Intensive Care Unit and prescribed support treatment. One day later, she was transferred to a conventional hospital room, with a good level of consciousness and normal neurological status, being able to self-criticize the facts, and confessing the intake of benzodiazepines and carbamazepine for autolytic purposes at a
moment when she did not feel able to handle the psychological stress caused by her family situation. The patient is discharged, with outpatient follow-up by Psychiatry Service, not detecting a psychiatric disorder, but remaining from now on in follow-up by a clinical psychologist to better manage the stress caused by her family situation.

4. Discussion

Acute intoxication by carbamazepine at high doses is a rare clinical event, being more common the presence of intoxications with other types of toxic substances such as benzodiazepines [12] or alcohol [13,14], however, in a patient with an abnormal neurological situation and with concomitant antiepileptic drugs use, these should be monitored, given the wide availability to determine the levels of them in plasma, so that scenarios like the one that encompasses us do not go unnoticed, and which may require specific urgent management.

As we know intoxication depends on both pharmacodynamics and pharmacokinetics of each drug, we must act in both spheres.

In general, if too much time has not passed since carbamazepine was ingested (no longer than that corresponding to its digestive absorption), treatment with activated charcoal is recommended. Multiple-dose activated charcoal is more efficient [15] than simple-dose; it permits a constant decrease of the half-life of blood CBZ without any rebound effect and could improve the prognosis by reducing the duration of coma and the length of stay.

Another therapeutic option, although not performed in the case report we present, would be the combination of continuous renal replacement therapy with hemoperfusion, which can be easily deployed, appears safe, and is able to combine the carbamazepine mass removal achieved with each technique, thus to maximize carbamazepine extraction [16].

In these cases, above all, the control of possible alterations in the cardiological sphere is of paramount importance. Two major clinical pictures can occur in this regard: sinus tachycardias in the setting of a massive carbamazepine overdose, and the other one is restricted almost exclusively of elderly women who develops potentially life-threatening bradyarrhythmias or atrioventricular conduction delay, associated with either therapeutic or modestly elevated carbamazepine serum levels [17]. Prompt management of both tables is crucial.

No less important will be to carry out an adequate assessment and follow-up in the psychiatric sphere, when the intoxication has been motivated by suicidal purposes.

Finally, although it has been reported infrequently, one of the effects of carbamazepine intoxication to be taken into account is the appearance of hyperglycemia, such as the one that can be seen in the case report at hand [18].

Author Contributions: Treatment of the patient, M.D.C.G. and M.A.G.; methodology, M.D.C.G.; writing—original draft preparation, M.D.C.G.; writing—review and editing, M.D.C.G. All authors have read and agreed to the published version of the manuscript.

Funding: This study has been funded by Instituto de Salud Carlos III (ISCIII) through the project “PI19/01364” and co-funded by the European Union.

Informed Consent Statement: Patient consent was waived due to not include identifiable patient information.

Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Missio, G.; Moreno, D.H.; Demetrio, F.N.; Soeiro-de-Souza, M.G.; Fernandes, F.D.S.; Barros, V.B.; Moreno, R.A. A randomized controlled trial comparing lithium plus valproic acid versus lithium plus carbamazepine in young patients with type 1 bipolar disorder: The LICAVAL study. Trials 2019, 20, 608–609. [CrossRef] [PubMed]
2. Huband, N.; Ferriter, M.; Nathan, R.; Jones, H. Antiepileptics for aggression and associated impulsivity. Cochrane Database Syst. Rev. 2010, 2010, CD003499. [CrossRef] [PubMed]
3. Bendtsen, L.; Zakrzewska, J.M.; Heinskou, T.B.; Hodaie, M.; Leal, P.R.L.; Nurmikko, T.; Obermann, M.; Cruccu, G.; Maarbjerg, S. Advances in diagnosis, classification, pathophysiology, and management of trigeminal neuralgia. *Lancet Neurol.* 2020, 19, 784–796. [CrossRef]

4. Brodie, M.J. Sodium Channel Blockers in the Treatment of Epilepsy. *CNS Drugs* 2017, 31, 527–534. [CrossRef] [PubMed]

5. Davies, J.A. Mechanisms of action of antiepileptic drugs. *Seizure* 1995, 4, 267–271. [CrossRef]

6. Spiller, H.A. Management of carbamazepine overdose. *Pediatr. Emerg. Care* 2001, 17, 452–456. [CrossRef] [PubMed]

7. Bertilsson, L.; Bertilsson, L.; Tomson, T. Clinical Pharmacokinetics and Pharmacological Effects of Carbamazepine and Carbamazepine-10,11-Epoxide. *Clin. Pharmacokinet.* 1986, 11, 177–198. [CrossRef] [PubMed]

8. Nogué Xarau, S. Chapter 67. Tóxicos Específicos. In *Toxicología Clínica*; Elsevier: Barcelona, Spain, 2019.

9. Hirsch, A.; Wanounou, M.; Perlman, A.; Hirsh-Raccah, B.; Muszkat, M. The effect of multidrug exposure on neurological manifestations in carbamazepine intoxication: A nested case-control study. *BMC Pharmacol. Toxicol.* 2020, 21, 47. [CrossRef] [PubMed]

10. Seymour, J.F. Carbamazepine Overdose. Features of 33 cases. *Drug Saf.* 1993, 8, 81–88. [CrossRef] [PubMed]

11. Edlow, J.A.; Rabinstein, A.; Traub, S.J.; Wijdicks, E.F.M. Diagnosis of reversible causes of coma. *Lancet* 2014, 384, 2064–2076. [CrossRef] [PubMed]

12. Dodds, T.J. Prescribed Benzodiazepines and Suicide Risk: A Review of the Literature. *Prim. Care Companion CNS Disord.* 2017, 19. [CrossRef] [PubMed]

13. Yuodelis-Flores, C.; Ries, R.K. Addiction and suicide: A review. *Am. J. Addict.* 2015, 24, 98–104. [CrossRef] [PubMed]

14. Hsu, W.-Y.; Chang, T.-G.; Chang, C.-C.; Chiu, N.-Y.; Lin, C.-H.; Lane, H.-Y. Suicide Ideation among Outpatients with Alcohol Use Disorder. *Behav. Neurol.* 2022, 2022, 4138629. [CrossRef] [PubMed]

15. Brahim, N.; Kouraichi, N.; Thabet, H.; Amamou, M. Influence of activated charcoal on the pharmacokinetics and the clinical features of carbamazepine poisoning. *Am. J. Emerg. Med.* 2006, 24, 440–443. [CrossRef] [PubMed]

16. Baylis, S.; Costa-Pinto, R.; Hodgson, S.; Bellomo, R.; Baldwin, I. Combined Hemoperfusion and Continuous Veno-Venous Hemofiltration for Carbamazepine Intoxication. *Blood Purif.* 2021, 1–5. [CrossRef] [PubMed]

17. Kasarskis, E.J.; Kuo, C.S.; Berger, R.; Nelson, K.R. Carbamazepine-induced cardiac dysfunction. Characterization of two distinct clinical syndromes. *Arch. Intern. Med.* 1992, 152, 186–191. [CrossRef]

18. Harika, V.; Parveen, S.; Venkatasubbiah, M.; Varma, K.S.; Devasree, S. Carbamazepine-induced hyperglycemia: A rare case report. *Indian J. Pharmacol.* 2019, 51, 352–353. [CrossRef]